Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research, development, production and sales of pharmaceutical products primarily in China. The company offers chemical drugs covering specialty categories including anti-tumor drugs, digestive drugs and parenteral nutritional drugs; anti-infective drugs; nanocarbon suspension injections (cannalin); esomeprazole sodium for injections; cefopoxime dry suspensions; esomeprazole magnesium enteric capsules; voriconazole active pharmaceutical ingredient; clindamycin hydrochloride injections; fludarabine phosphate for injections; ammonium succinate for injections; sodium methylprednisolone hydrochloride injections; as well as anti-inflammatory, antibacterial, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal and opioid receptor antagonists. It operates mainly in the domestic Chinese market with a focus on hospitals and pharmaceutical distributors; founded in 1999 and headquartered in Chongqing, China. In recent developments, a holding subsidiary of its indirect controlling shareholder Guangxi Wuzhou Zhongheng Group obtains regulatory approval from the National Medical Products Administration for supplemental applications of clindamycin phosphate injection in two specifications; the company receives registration certificates for products such as azithromycin granules and passes consistency evaluations for antibiotics; its influenza drug passes hospital ethical review; and it discloses a potential change in indirect controlling shareholder as Guangxi Investment Group Financial Holding increases its stake in the parent entity, alongside participation in industry buyout funds and partnerships for strategic investments in the pharmaceutical sector.